test

Outcomes

Yale Cancer Center and our partner, Smilow Cancer Hospital at Yale-New Haven, acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers.  The latest performance data for breast center is listed below.

Breast Cancer Performance Rates

Patient Outcomes
  1. Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year of diagnosis for women with T1c N0 M0, or sate II or III ERA and/or PRA positive breast cancer.
  2. Radiation therapy is administered within 1 year of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.
  3. Combination chemotherapy is considered or administered within 4 months of diagnosis for women under age 70 with T1c N0 M0, or stafe II or III ERA and PRA negative breast cancer.